Drug Trial Radar · NCT01619865
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
223
Actual
Start
Feb 21, 2012
Primary completion
Aug 27, 2017
Study completion Aug 27, 2017
Sponsor
- Lead sponsor
- Sue O'DorisioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.
Conditions
- Neuroendocrine Tumors
- Carcinoid Tumors
- Neuroblastoma
- Medulloblastoma
Interventions
68Ga-DOTATOC PET/CTDrug
1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical AgentTime frame: During PET scan and 24 hours post scan
- Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOCTime frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Iowa Health Care
Iowa City, Iowa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.